| 英文别名 |
3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-;(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane;ABT 894;A 422894.0;Sofiniclin;(1S,5S)-3-(5,6-Dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane (ACI);3-(5,6-Dichloropyridin-3-yl)-(1S,5S)-3,6-diazabicyclo[3.2.0]heptane;A 422894;Sofinicline;Sofinicline (USAN);ZGB27980;3,6-Diazabicyclo(3.2.0)heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)-;ABT-894;UNII-SQC232V4YY;(1S, 5S)-3-(5,6-Dichloro-pyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane;(1S,5 S)-3-(5,6-Dichloro-pyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane;CS-6792;799279-80-4 (free base);SCHEMBL650488;D09382;(-)-(1S,5S)-3-(5,6-DICHLOROPYRIDIN-3-YL)-3,6-DIAZABICYCLO(3.2.0)HEPTANE;AKOS040732367;Sofinicline [USAN];DTXSID901000842;NS00071854;(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane;(1S,5 S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane;SOFINICLINE [WHO-DD];3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane;(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]-heptane;(1S,5S)-3-(5,6-Dichloro-pyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane;BDBM50224483;Sofinicline [USAN:INN];Q27289342;A-422894.0;CHEMBL238465;MBQYQLWSBRANKQ-IMTBSYHQSA-N;SQC232V4YY;SOFINICLINE [INN];MS-23449;DB12527;(1S, 5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diaza-bicyclo[3.2.0]heptane;HY-14824;EX-A5733;799279-80-4;sofiniclinum;G14038;sofiniclina;(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo(3.2.0)heptane;DA-50097 |
